Therefore, the study’s primary end-point was to investigate whether IL-6 -174 G>C and TNF-α -376 G>A polymorphisms could be correlated to the incidence of FLS in MS patients who started IFNβ-1a IM therapy. The gene discussed is TNF; the disease is myeloid sarcoma.